Gene Therapy Market
Gene Therapy Market By Vectors Type (Diagnostic Supplies, Infusion & Injectable Supplies, Intubation & Ventilation Supplies), By Indication Type (Urology, Wound Care, Radiology), And By Gene Type (Hospitals, Clinics/Physician Offices, Other Gene Types) - Forecast Year 2024 – 2031
Healthcare // Advanced Genetic Sequencing
The global Gene
Therapy market is foreseen to grow by 20.1%, from USD 6.95 Billion in 2022 to
USD 30.16 Billion in 2030. High incidence of cancer and other target diseases,
product approvals, funding for gene therapy research is to drive the market for
the upcoming forecast period. However, high treatment costs remains one factor
hindering the market growth over the anticipated period.
Market Definition
Gene Therapy refer to equipment, devices, and
other consumables used by medical professionals to diagnose, treat, and prevent
diseases or injuries. These products range from simple bandages and syringes to
complex machinery like MRI machines and surgical robots. Gene Therapy are an
essential part of the healthcare industry and are crucial in providing quality
medical care to patients.
Market Overview
Gene Therapy: The Future of Medicine
Gene therapy is
an innovative field of medicine that is rapidly gaining momentum in the
healthcare industry. It is a technique that involves the delivery of genetic
material into a patient's cells to treat or prevent diseases. This approach is
promising because it addresses the underlying cause of a disease, rather than
simply treating its symptoms. This essay will explore the potential of gene
therapy and how it works, as well as its benefits and challenges.
How Gene Therapy Works
Gene therapy
works by introducing new genetic material into a patient's cells. This genetic
material can be a functional copy of a missing or defective gene, or it can be
a new gene that produces a therapeutic protein. There are two main types of
gene therapy: in vivo and ex vivo.
In vivo gene
therapy involves delivering the genetic material directly to the patient's
cells in their body. This can be done through a variety of methods, such as
injection, infusion, or inhalation. Ex vivo gene therapy involves removing
cells from the patient, modifying them in the lab, and then returning them to
the patient's body. This method is often used when a patient's cells need to be
edited or modified before being returned to the body.
Benefits of Gene Therapy
One of the
biggest benefits of gene therapy is its potential to cure genetic disorders
that were previously untreatable. Diseases like cystic fibrosis, sickle cell
anemia, and Huntington's disease can all be treated with gene therapy.
Additionally, gene therapy can also be used to treat non-genetic diseases like
cancer, heart disease, and HIV. Gene therapy is also a potential cure for many
rare diseases that affect a small number of people.
Another benefit
of gene therapy is that it can be a one-time treatment. Unlike traditional
medicines, which often require daily or weekly doses, gene therapy can provide
a long-lasting cure. This can save patients time and money, as well as reduce
the burden on healthcare systems.
Challenges of Gene Therapy
While gene
therapy has the potential to revolutionize medicine, there are still several
challenges that need to be addressed. One of the main challenges is the
delivery of the genetic material to the patient's cells. The genetic material
needs to be delivered to the right cells and in the right amount. This can be
difficult, especially if the patient has a large number of cells that need to
be modified.
Another
challenge is the potential for unintended consequences. The genetic material
that is introduced into the patient's cells could have unintended effects. For
example, it could disrupt other genes or trigger an immune response.
Additionally, gene therapy is still a relatively new field, and there is much
that is still unknown about its long-term effects.
Conclusion
Gene therapy is
a promising field of medicine that has the potential to revolutionize how we
treat diseases. It offers a potential cure for genetic disorders that were
previously untreatable and could be a one-time treatment for many diseases.
However, there are still many challenges that need to be addressed before gene
therapy can become a mainstream treatment. With continued research and
development, it is likely that gene therapy will play an increasingly important
role in the future of medicine.
Gene Therapy Market Dynamics:
The increasing
focus on gene therapy as a promising treatment for cancer and genetic diseases
has driven the growth of research in this area. As a result, companies are
launching new and advanced products to capitalize on opportunities in the gene
therapy market. Funding for gene therapy research is also on the rise, with
recent examples including a USD 12 million grant from the National Heart Lung
and Blood Institute to an Indiana University School of Medicine researcher in
March 2022 for exploring safer and potentially curative treatments for
hemophilia. Another example is Locana, Inc., which received USD 55 million in
Series A financing in May 2019 from existing investors such as ARCH Venture
Partners, Temasek, and Lightstone Ventures for its RNA-targeting gene therapy
pipeline programs.
Opportunities: Strong Product Pipeline
The field of
gene therapy presents a promising avenue for revenue generation for
pharmaceutical and biotechnology companies. Key players in the industry are
currently concentrating on the development of new gene therapy products to take
advantage of the growing market opportunities. These products are in various
stages of development, with some still in the pre-clinical phase while others
are undergoing clinical trials and expected to be approved in the near future.
Gene therapy companies are targeting a range of disease areas, including
hemophilia, Fabry disease, wet age-related macular degeneration, and multiple
myeloma, which are expected to increase the patient pool for gene therapies.
Challenges: High Treatment Cost
One of the
major challenges faced by the gene therapy industry is the high cost of
treatment. The cost of gene therapies can reach up to USD 1 million per
patient, depending on the disease condition. Although most gene therapy
products in the US and EU are covered under reimbursement programs, it is still
difficult for people who are not covered by insurance to afford such
treatments.
Non-Viral Vectors Segment Dominates the Gene Therapy Market
The gene
therapy market is segmented into non-viral vectors and viral vectors based on
vectors. Non-viral vectors held the largest market share in 2021. The growth of
this segment is being driven by factors such as the lower immunogenicity of
non-viral vectors in comparison to viral vectors and the ease of mass
production.
In 2021, the
largest share of the global gene therapy industry was attributed to North
America. This can be attributed to the considerable investments made by both
the government and private sectors to develop more advanced gene therapy
products. Furthermore, the high adoption rate of these products in the region
and the presence of key market players also contribute to the significant
market share of North America in the global gene therapy market.
Market Segmentation
For the purpose
of this report, the global gene therapy market segmented on the basis of vectors
type, indication type, gene type, delivery method and region:
Vectors Type Outlook:
On the basis of
vectors type, the market is segmented into non-viral vectors, viral vectors. Further,
non-viral vectors is segmented into oligonucleotides, other non-viral vectors. Further,
viral vectors is segmented into retro viral vectors, adeno-associated virus
vectors, other viral vectors.
Indication Type Outlook:
On the basis of
Indication Type, the market is segmented into Neurological Diseases, Cancer,
DMD (Duchenne Muscular Dystrophy), Hepatological Diseases, Other Indications.
Gene Type Outlook:
On the basis of
Gene Type, the market is segmented into Antigen, Cytokine, Tumor Suppressor,
Suicide, Deficiency, Growth factors, Receptors, Others.
Figure 1 Gene Therapy Market By Gene Type (Market Size And Forecast By Value - USD Million, 2022 & 2030)
Delivery Method Outlook:
On the basis of
delivery method, the market is segmented into in vivo, ex vivo.
Regional Outlook (Revenue, USD Million; 2022 & 2030)
|
Regional Outlook
(Revenue, USD Million; 2020-2030) |
|
|
North America |
U.S. |
|
Canada |
|
|
Europe |
Germany |
|
U.K. |
|
|
France |
|
|
Spain |
|
|
Italy |
|
|
Rest of the Europe |
|
|
Asia Pacific |
India |
|
Japan |
|
|
China |
|
|
South Korea |
|
|
Australia |
|
|
Rest of Asia-Pacific |
|
|
Middle East & Africa |
UAE |
|
Saudi Arabia |
|
|
South Africa |
|
|
Rest of Middle East & Africa |
|
|
Latin America |
Brazil |
|
Mexico |
|
|
Argentina |
|
|
Rest of Latin America |
|
An exclusive gene
therapy market research report provides an in-depth analysis of the market
dynamics across five regions: North America, Europe, South America,
Asia-Pacific, Middle East, and Africa. Furthermore, the market has been
evaluated by utilizing diverse research methodologies and internal statistical model.
Companies Considered And Profiled In This Market Study
The players
operating in the market have undertaken several strategies related to the
market in the period 2020-2022. some of the prominent players in the gene
therapy market include
· Agc Biologics
· Agtc (Applied
Genetic Technologies Corporation)
· Amgen, Inc.
· Anges, Inc.
· Biogen
· Bluebird Bio, Inc.
· Celgene Corporation
(A Bristol-Myers Squibb Company)
· Cellectis
· Dynavax
Technologies
· Gensight Biologics
S.A.
· Gilead Sciences,
Inc.
· Human Stem Cells
Institute
· Jazz
Pharmaceuticals Plc
· Mustang Bio
· Novartis Ag
· Orchard
Therapeutics Plc
· Poseida
Therapeutics, Inc.
· Sangamo
Therapeutics
· Sarepta
Therapeutics
· Shanghai Sunway
Biotech Co., Ltd.
· Sibiono Genetech
Co., Ltd.
· Spark Therapeutics,
Inc. (An F. Hoffmann-La Roche Company)
· Uniqure N.V.
Global Gene Therapy Market Report Scope
|
Historical
data |
2020 - 2021 |
|
Base
year for estimation |
2022 |
|
Forecast
period |
2023 - 2030 |
|
Market
size value in 2022 |
USD 6.95
Billion |
|
Revenue
forecast in 2030 |
USD 30.16 Billion |
|
Growth
Rate |
CAGR of 20.1%
from 2023 to 2030 |
|
Quantitative
units |
Revenue in USD Million/Billion & CAGR
from 2023 to 2030 |
|
Report
coverage |
Revenue
forecast, company share, competitive landscape, growth factors, and trends |
|
Segments
covered |
Vectors Type, Indication Type, Gene Type, Delivery
Method |
|
Key
companies profiled |
Biogen, Sarepta
Therapeutics, Gilead Sciences, Inc. |
|
Regional
Scope |
North America, Europe, Asia Pacific, Middle
East & Africa, Latin America |
|
Country
Scope |
U.S.,
Canada, Germany, U.K., France, Italy, Spain, India, Japan, China, Australia,
South Korea, Saudi Arabia, UAE, South Africa, Brazil, Mexico, Argentina |
|
Customization
scope |
Free report customization (equivalent to up
to 8 analysts’ working days) with purchase. Addition or alteration to
country, regional & segment scope. |
Vectors Type Outlook (Revenue, USD Million/Billion; 2020-2030)
· Non-viral Vectors
o Oligonucleotides
o Other Non-viral
Vectors
· Viral Vectors
o Retro Viral Vectors
o Adeno-associated
Virus Vectors
o Other Viral Vectors
Indication Type Outlook (Revenue, USD Million/Billion; 2020-2030)
· Neurological
Diseases
· Cancer
· DMD (Duchenne
Muscular Dystrophy)
· Hepatological
Diseases
· Other Indications
Gene Type Outlook (Revenue, USD Million/Billion; 2020-2030)
· Antigen
· Cytokine
· Tumor Suppressor
· Suicide
· Deficiency
· Growth factors
· Receptors
· Others
Delivery Method Outlook (Revenue, USD Million/Billion; 2020-2030)
· In Vivo
· Ex Vivo
Regional Outlook (Revenue, USD Million/Billion; 2020-2030)
· North America
o U.S.
o Canada
· Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of the Europe
· Asia Pacific
o India
o Japan
o China
o South Korea
o Australia
o Rest of
Asia-Pacific
· Middle East &
Africa
o UAE
o Saudi Arabia
o South Africa
o Rest of Middle East
& Africa
· Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin
America
Recent Developments in Gene Therapy Market
The gene
therapy market has seen recent developments in the form of collaborations and
product approvals. Sarepta Therapeutics in the US announced in February 2022
that it would collaborate with GenEdit's NanoGalaxy platform and its gene
editing technology to develop gene editing therapeutics to treat neuromuscular
diseases. This collaboration aims to develop more effective treatments for
neuromuscular diseases using gene editing techniques.
In May 2022,
Novartis AG in Switzerland received approval from the FDA for KYMRIAH to treat
adult patients with relapsed or refractory follicular lymphoma after two or
more lines of systemic therapy. KYMRIAH is a gene therapy that involves
genetically modifying the patient's own immune cells to recognize and attack
cancer cells. This approval demonstrates the growing potential of gene therapy
as a viable treatment option for various diseases, including cancer.
Recent
developments in the Gene Therapy Market indicate that the industry is
experiencing significant growth and advancements. Some notable developments
are:
In February
2022, the FDA approved the gene therapy product Zolgensma for the treatment of
pediatric patients with spinal muscular atrophy (SMA). Zolgensma is a one-time
gene therapy that addresses the root cause of SMA by replacing the missing or
nonfunctional SMN1 gene with a functional copy of the SMN1 gene.
In September
2021, the European Commission granted conditional marketing authorization for
Zynteglo, a gene therapy product for patients with transfusion-dependent
beta-thalassemia. Zynteglo is a one-time gene therapy that uses a viral vector
to deliver a functional copy of the beta-globin gene into a patient's stem
cells, allowing for the production of hemoglobin and reducing or eliminating
the need for blood transfusions.
In October
2021, bluebird bio announced that it had completed its rolling submission of
its gene therapy product LentiGlobin for the treatment of sickle cell disease
to the FDA. LentiGlobin is a one-time gene therapy that uses a viral vector to
deliver a functional copy of the beta-globin gene into a patient's stem cells,
allowing for the production of healthy red blood cells.
In November
2021, Regenxbio announced positive interim data from a Phase II clinical trial
of its gene therapy product RGX-121 for the treatment of mucopolysaccharidosis
type II (MPS II), also known as Hunter syndrome. RGX-121 is a one-time gene
therapy that uses a viral vector to deliver a functional copy of the IDS gene
into a patient's cells, allowing for the production of the missing IDS enzyme.
These recent
developments in the Gene Therapy Market demonstrate the industry's commitment
to innovation and the development of new gene therapies to address unmet
medical needs. The FDA and European Commission's approvals of gene therapy
products show the growing acceptance of gene therapy as a viable treatment option
for certain genetic disorders.
|
Chapter
1. Introduction |
|
|
1.1. Market Definition |
|
|
1.2. Research Scope |
|
|
1.2.1. Markets Covered |
|
|
1.2.2. Years Considered for
Study |
|
|
Chapter 2. Executive
Summary |
|
|
2.1. Summary Snapshot Market Size
and Forecast, 2020-2030 |
|
|
2.2. Gene Therapy Market Share by
Vectors Type, 2022 vs 2030 (USD Million) |
|
|
2.3. Gene Therapy Market Share by
Indication Type, 2022 vs 2030 (USD Million) |
|
|
2.4. Gene Therapy Market Share by Gene
Type, 2022 vs 2030 (USD Million) |
|
|
2.5. Gene Therapy Market Share by
Delivery Method, 2022 vs 2030 (USD Million) |
|
|
2.6. Gene Therapy Market Share by
Region, 2022 vs 2030 (USD Million) |
|
|
Chapter 3. Key Insights |
|
|
Chapter 4. Gene Therapy
Market Segmentation & Impact Analysis |
|
|
4.1. Gene Therapy Market Indicators
Analysis |
|
|
4.1.1. Market Drivers
Analysis |
|
|
4.1.1.1. High
incidence of cancer and other target diseases |
|
|
4.1.1.2. Product approvals |
|
|
4.1.1.3. Funding for
gene therapy research |
|
|
4.1.2. Market Restraint
Analysis |
|
|
4.1.2.1. High
treatment costs |
|
|
4.1.3. Market Opportunity
Analysis |
|
|
4.1.3.1. Strong
product pipeline |
|
|
4.1.3.2. |
|
|
4.2. Regulatory Analysis |
|
|
4.2.1. North America |
|
|
4.2.1.1. U.S. |
|
|
4.2.1.2. Canada |
|
|
4.2.2. Europe |
|
|
4.2.3. Asia Pacific |
|
|
4.2.3.1. India |
|
|
4.2.3.2. Japan |
|
|
4.2.3.3. China |
|
|
4.3. Technological Insights |
|
|
4.4. COVID-19 Impact analysis on Gene
Therapy Market |
|
|
4.5. Porter’s Five Forces Analysis |
|
|
4.5.1. Bargaining Power of
Buyers/Consumers |
|
|
4.5.2. Bargaining Power of
Suppliers |
|
|
4.5.3. Threat of New Entrants |
|
|
4.5.4. Threat of Substitute
Products |
|
|
4.5.5. Intensity of Competitive
Rivalry |
|
|
4.6. Competitive Metric Space Analysis |
|
|
Chapter 5. Gene
Therapy Market, By Vectors Type (Market Size and Forecast by Value - USD
Million, 2020 - 2030) |
|
|
5.1. Gene Therapy Market, By Vectors
Type (Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
|
5.1.1. Non-viral Vectors |
|
|
5.1.1.1. Non-viral Vectors Market Estimates and
Forecast, 2020-2030 (USD Million) |
|
|
5.1.1.2. Non-viral Vectors Market Estimates and
Forecast, By Region, 2020-2030 (USD Million) |
|
|
5.1.2. Viral Vectors |
|
|
5.1.2.1. Viral
Vectors Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
5.1.2.2. Viral
Vectors Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
Chapter 6. Gene
Therapy Market, By Indication Type (Market Size and Forecast by Value - USD
Million, 2020 - 2030) |
|
|
6.1. Gene Therapy Market, By Indication
Type (Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
|
6.1.1. Neurological Diseases |
|
|
6.1.1.1. Neurological Diseases Market Estimates and
Forecast, 2020-2030 (USD Million) |
|
|
6.1.1.2. Neurological Diseases Market Estimates and
Forecast, By Region, 2020-2030 (USD Million) |
|
|
6.1.2. Cancer |
|
|
6.1.2.1. Cancer Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
6.1.2.2. Cancer Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
6.1.3. DMD (Duchenne Muscular
Dystrophy) |
|
|
6.1.3.1. DMD
(Duchenne Muscular Dystrophy) Market Estimates and Forecast, 2020-2030 (USD
Million) |
|
|
6.1.3.2. DMD
(Duchenne Muscular Dystrophy) Market Estimates and Forecast, By Region,
2020-2030 (USD Million) |
|
|
6.1.4. Hepatological Diseases |
|
|
6.1.4.1.
Hepatological Diseases Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
6.1.4.2. Hepatological
Diseases Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
6.1.5. Other Indications |
|
|
6.1.5.1. Other
Indications Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
6.1.5.2. Other Indications Market
Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
Chapter 7. Gene
Therapy Market, By Gene Type (Market Size and Forecast by Value - USD
Million, 2020 - 2030) |
|
|
7.1. Gene Therapy Market, By Gene Type
(Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
|
7.1.1. Antigen |
|
|
7.1.1.1. Antigen Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
7.1.1.2. Antigen Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
7.1.2. Cytokine |
|
|
7.1.2.1. Cytokine Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
7.1.2.2. Cytokine Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
7.1.3. Tumor Suppressor |
|
|
7.1.3.1. Tumor
Suppressor Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
7.1.3.2. Tumor Suppressor
Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
7.1.4. Suicide |
|
|
7.1.4.1. Suicide
Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
7.1.4.2. Suicide
Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
7.1.5. Deficiency |
|
|
7.1.5.1. Deficiency
Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
7.1.5.2. Deficiency
Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
Chapter 8. Gene
Therapy Market, By Delivery Method (Market Size and Forecast by Value - USD
Million, 2020 - 2030) |
|
|
8.1. Gene Therapy Market, By Delivery
Method (Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
|
8.1.1. In Vivo |
|
|
8.1.1.1. In Vivo Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
8.1.1.2. In Vivo Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
8.1.2. Ex Vivo |
|
|
8.1.2.1. Ex Vivo Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
8.1.2.2. Ex Vivo Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
Chapter 9. Gene Therapy
Market, By Region (Market Size and Forecast by Value - USD Million, 2020 -
2030) |
|
|
9.1. Gene Therapy Market, By Region
(Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
|
9.2. North America |
|
|
9.2.1. North America Gene
Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.2.2. North America Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.2.3. North America Gene
Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.2.4. North America Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.2.5. North America Gene
Therapy Market, By Country, 2020-2030 (USD Million) |
|
|
9.2.6. U.S. |
|
|
9.2.6.1. U.S.
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.2.6.2. U.S.
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.2.6.3. U.S.
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.2.6.4. U.S. Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.2.7. Canada |
|
|
9.2.7.1. Canada
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.2.7.2. Canada Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.2.7.3. Canada
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.2.7.4. Canada
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.3. Europe |
|
|
9.3.1. Europe Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.3.2. Europe Gene Therapy Market,
By Indication Type, 2020-2030 (USD Million) |
|
|
9.3.3. Europe Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.3.4. EuropeGene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.3.5. Europe Gene Therapy
Market, By Country, 2020-2030 (USD Million) |
|
|
9.3.6. Germany |
|
|
9.3.6.1. Germany
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.3.6.2. Germany
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.3.6.3. Germany
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.3.6.4. Germany
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.3.7. U.K. |
|
|
9.3.7.1. U.K.
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.3.7.2. U.K. Gene
Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.3.7.3. U.K.
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.3.7.4. U.K.
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.3.8. France |
|
|
9.3.8.1. France
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.3.8.2. France
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.3.8.3. France
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.3.8.4. France Gene
Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.3.9. Spain |
|
|
9.3.9.1. Spain
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.3.9.2. Spain
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.3.9.3. Spain
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.3.9.4. Spain
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.3.10. Italy |
|
|
9.3.10.1. Italy
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.3.10.2. Italy Gene
Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.3.10.3. Italy
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.3.10.4. Italy
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.3.11. Rest of Europe |
|
|
9.3.11.1. Rest of
Europe Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.3.11.2. Rest of
Europe Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.3.11.3. Rest of
Europe Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.3.11.4. Rest of
Europe Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.4. Asia Pacific |
|
|
9.4.1. Asia Pacific Gene
Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.4.2. Asia Pacific Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.4.3. Asia Pacific Gene
Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.4.4. Asia Pacific Gene
Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.4.5. Asia Pacific Gene
Therapy Market, By Country, 2020-2030 (USD Million) |
|
|
9.4.6. India |
|
|
9.4.6.1. India
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.4.6.2. India Gene Therapy Market, By
Indication Type, 2020-2030 (USD Million) |
|
|
9.4.6.3. India
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.4.6.4. India Gene
Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.4.7. Japan |
|
|
9.4.7.1. Japan
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.4.7.2. Japan
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.4.7.3. Japan
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.4.7.4. Japan
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.4.8. China |
|
|
9.4.8.1. China
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.4.8.2. China Gene
Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.4.8.3. China
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.4.8.4. China
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.4.9. South Korea |
|
|
9.4.9.1. South
Korea Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.4.9.2. South
Korea Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.4.9.3. South
Korea Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.4.9.4. South
Korea Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.4.10. Australia |
|
|
9.4.10.1.
Australia Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.4.10.2. Australia
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.4.10.3.
Australia Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.4.10.4.
Australia Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.4.11. Rest of Asia Pacific |
|
|
9.4.11.1. Rest of
Asia Pacific Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.4.11.2. Rest of
Asia Pacific Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.4.11.3. Rest of
Asia Pacific Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.4.11.4. Rest of
Asia Pacific Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.5. Middle East & Africa |
|
|
9.5.1. Middle East & Africa
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.5.2. Middle East & Africa
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.5.3. Middle East & Africa
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.5.4. Middle East & Africa
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.5.5. Middle East & Africa
Gene Therapy Market, By Country, 2020-2030 (USD Million) |
|
|
9.5.6. UAE |
|
|
9.5.6.1. UAE Gene
Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.5.6.2. UAE Gene
Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.5.6.3. UAE Gene
Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.5.6.4. UAE Gene
Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.5.7. Saudi Arabia |
|
|
9.5.7.1. Saudi
Arabia Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.5.7.2. Saudi
Arabia Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.5.7.3. Saudi
Arabia Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.5.7.4. Saudi
Arabia Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.5.8. South Africa |
|
|
9.5.8.1. South Africa
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.5.8.2. South
Africa Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.5.8.3. South
Africa Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.5.8.4. South
Africa Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.5.9. Rest of Middle East
& Africa |
|
|
9.5.9.1. Rest of
Middle East & Africa Gene Therapy Market, By Vectors Type, 2020-2030 (USD
Million) |
|
|
9.5.9.2. Rest of
Middle East & Africa Gene Therapy Market, By Indication Type, 2020-2030
(USD Million) |
|
|
9.5.9.3. Rest of
Middle East & Africa Gene Therapy Market, By Gene Type, 2020-2030 (USD
Million) |
|
|
9.5.9.4. Rest of
Middle East & Africa Gene Therapy Market, By Delivery Method, 2020-2030
(USD Million) |
|
|
9.6. Latin America |
|
|
9.6.1. Latin America Gene
Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.6.2. Latin America Gene
Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.6.3. Latin America Gene
Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.6.4. Latin America Gene
Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.6.5. Latin America Gene Therapy
Market, By Country, 2020-2030 (USD Million) |
|
|
9.6.6. Brazil |
|
|
9.6.6.1. Brazil
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.6.6.2. Brazil
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.6.6.3. Brazil
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.6.6.4. Brazil
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.6.7. Mexico |
|
|
9.6.7.1. Mexico
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.6.7.2. Mexico
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.6.7.3. Mexico
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.6.7.4. Mexico
Gene Therapy Market, By 10A, 2020-2030 (USD Million) |
|
|
9.6.8. Argentina |
|
|
9.6.8.1. Argentina Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.6.8.2.
Argentina Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.6.8.3.
Argentina Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.6.8.4.
Argentina Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
|
9.6.9. Rest of Latin America |
|
|
9.6.9.1. Rest of
Latin America Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
|
9.6.9.2. Rest of Latin
America Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
|
9.6.9.3. Rest of
Latin America Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
|
9.6.9.4. Rest of
Latin America Gene Therapy Market, By Delivery Method, 2020-2030 (USD
Million) |
|
|
Chapter 10. Competitive Landscape |
|
|
10.1. Market Revenue Share by
Manufacturers |
|
|
10.2. Competitor’s Positioning |
|
|
10.3. Strategy Benchmarking |
|
|
10.3.1. Partnership &
Agreement |
|
|
10.3.2. New Product
Development |
|
|
10.3.3. Mergers &
Acquisitions |
|
|
10.3.4. Investment &
Expansion |
|
|
10.4. Vendor Landscape |
|
|
10.4.1. Distributors |
|
|
10.4.2. North America |
|
|
10.4.3. Europe |
|
|
10.4.4. Asia Pacific |
|
|
10.4.5. Middle East &
Africa |
|
|
10.4.6. Latin America |
|
|
10.5. Zettabyte Analytics Insights for
Competitive Landscape |
|
|
Chapter 11. Company
Profiles |
|
|
11.1. Agc Biologics |
|
|
11.1.1. Company Overview |
|
|
11.1.2. Products Offered |
|
|
11.1.3. Financials |
|
|
11.1.4. Recent
Development |
|
|
11.2. Agtc (Applied Genetic Technologies
Corporation) |
|
|
11.2.1. Company Overview |
|
|
11.2.2. Products Offered |
|
|
11.2.3. Financials |
|
|
11.2.4. Recent
Development |
|
|
11.3. Amgen, Inc. |
|
|
11.3.1. Company Overview |
|
|
11.3.2. Products Offered |
|
|
11.3.3. Financials |
|
|
11.3.4. Recent Development |
|
|
11.4. Anges, Inc. |
|
|
11.4.1. Company Overview |
|
|
11.4.2. Products Offered |
|
|
11.4.3. Financials |
|
|
11.4.4. Recent
Development |
|
|
11.5. Biogen |
|
|
11.5.1. Company Overview |
|
|
11.5.2. Products Offered |
|
|
11.5.3. Financials |
|
|
11.5.4. Recent
Development |
|
|
11.6. Bluebird Bio, Inc. |
|
|
11.6.1. Company Overview |
|
|
11.6.2. Products Offered |
|
|
11.6.3. Financials |
|
|
11.6.4. Recent
Development |
|
|
11.7. Celgene Corporation (A
Bristol-Myers Squibb Company) |
|
|
11.7.1. Company Overview |
|
|
11.7.2. Products Offered |
|
|
11.7.3. Financials |
|
|
11.7.4. Recent
Development |
|
|
11.8. Cellectis |
|
|
11.8.1. Company Overview |
|
|
11.8.2. Products Offered |
|
|
11.8.3. Financials |
|
|
11.8.4. Recent
Development |
|
|
11.9. Dynavax Technologies |
|
|
11.9.1. Company Overview |
|
|
11.9.2. Products Offered |
|
|
11.9.3. Financials |
|
|
11.9.4. Recent Development |
|
|
11.10. Gensight Biologics S.A. |
|
|
11.10.1. Company Overview |
|
|
11.10.2. Products Offered |
|
|
11.10.3. Financials |
|
|
11.10.4. Recent
Development |
|
|
11.11. Gilead Sciences, Inc. |
|
|
11.11.1. Company Overview |
|
|
11.11.2. Products Offered |
|
|
11.11.3. Financials |
|
|
11.11.4. Recent
Development |
|
|
11.12. Human Stem Cells Institute |
|
|
11.12.1. Company Overview |
|
|
11.12.2. Products Offered |
|
|
11.12.3. Financials |
|
|
11.12.4. Recent
Development |
|
|
11.13. Jazz Pharmaceuticals Plc |
|
|
11.13.1. Company Overview |
|
|
11.13.2. Products Offered |
|
|
11.13.3. Financials |
|
|
11.13.4. Recent
Development |
|
|
11.14. Mustang Bio |
|
|
11.14.1. Company Overview |
|
|
11.14.2. Products Offered |
|
|
11.14.3. Financials |
|
|
11.14.4. Recent
Development |
|
|
11.15. Novartis Ag |
|
|
11.15.1. Company Overview |
|
|
11.15.2. Products Offered |
|
|
11.15.3. Financials |
|
|
11.15.4. Recent Development |
|
|
11.16. Orchard Therapeutics Plc |
|
|
11.16.1. Company Overview |
|
|
11.16.2. Products Offered |
|
|
11.16.3. Financials |
|
|
11.16.4. Recent
Development |
|
|
11.17. Poseida Therapeutics, Inc. |
|
|
11.17.1. Company Overview |
|
|
11.17.2. Products Offered |
|
|
11.17.3. Financials |
|
|
11.17.4. Recent
Development |
|
|
11.18. Sangamo Therapeutics |
|
|
11.18.1. Company Overview |
|
|
11.18.2. Products Offered |
|
|
11.18.3. Financials |
|
|
11.18.4. Recent
Development |
|
|
11.19. Sarepta Therapeutics |
|
|
11.19.1. Company Overview |
|
|
11.19.2. Products Offered |
|
|
11.19.3. Financials |
|
|
11.19.4. Recent
Development |
|
|
11.20. Shanghai Sunway Biotech Co., Ltd. |
|
|
11.20.1. Company Overview |
|
|
11.20.2. Products Offered |
|
|
11.20.3. Financials |
|
|
11.20.4. Recent
Development |
|
|
11.21. Sibiono Genetech Co., Ltd. |
|
|
11.21.1. Company Overview |
|
|
11.21.2. Products Offered |
|
|
11.21.3. Financials |
|
|
11.21.4. Recent
Development |
|
|
11.22. Spark Therapeutics, Inc. (An F.
Hoffmann-La Roche Company) |
|
|
11.22.1. Company Overview |
|
|
11.22.2. Products Offered |
|
|
11.22.3. Financials |
|
|
11.22.4. Recent
Development |
|
|
11.23. Uniqure N.V. |
|
|
11.23.1. Company Overview |
|
|
11.23.2. Products Offered |
|
|
11.23.3. Financials |
|
|
11.23.4. Recent
Development |
|
|
Chapter 12. Research
Methodology |
|
|
12.1. Research Sources |
|
|
12.1.1. Primary |
|
|
12.1.2. Secondary |
|
|
12.12. Market Size Estimation |
|
|
Chapter 13. Appendix |
|
|
13.1. Discussion guide |
|
|
13.2. Knowledge Store:
Zettabyte Analytics Subscription Portal |
|
|
13.3. Available
Customizations |
|
|
13.4. Associated
Zettabyte Analytics Reports |
|
|
List of Tables |
|
|
Table 1 |
Gene Therapy Market, By
Vectors Type (Market Size and Forecast by Value - USD Million, 2022 &
2030) |
|
Table 2 |
Non-viral Vectors Market
Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 3 |
Non-viral Vectors Market
Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 4 |
Viral Vectors Market
Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 5 |
Viral Vectors Market
Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 6 |
Gene Therapy Market, By
Indication Type (Market Size and Forecast by Value - USD Million, 2022 &
2030) |
|
Table 7 |
Neurological Diseases
Market Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 8 |
Neurological Diseases
Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 9 |
Gene Therapy Market, By
Gene Type (Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
Table 10 |
Antigen Market Estimates
and Forecast, 2020-2030 (USD Million) |
|
Table 11 |
Antigen Market Estimates
and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 12 |
Cytokine Market Estimates
and Forecast, 2020-2030 (USD Million) |
|
Table 13 |
Cytokine Market Estimates
and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 14 |
Tumor Suppressor Market
Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 15 |
Tumor Suppressor Market
Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 16 |
Gene Therapy Market, By
Delivery Method (Market Size and Forecast by Value - USD Million, 2022 &
2030) |
|
Table 17 |
In Vivo Market Estimates
and Forecast, 2020-2030 (USD Million) |
|
Table 18 |
In Vivo Market Estimates
and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 19 |
Ex Vivo Market Estimates
and Forecast, 2020-2030 (USD Million) |
|
Table 20 |
Ex Vivo Market Estimates
and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 21 |
North America Gene
Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 22 |
North America Gene
Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 23 |
North America Gene
Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 24 |
North America Gene
Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 25 |
North America Gene
Therapy Market, By Country, 2020-2030 (USD Million) |
|
Table 26 |
U.S. Gene Therapy Market,
By Vectors Type, 2020-2030 (USD Million) |
|
Table 27 |
U.S. Gene Therapy Market,
By Indication Type, 2020-2030 (USD Million) |
|
Table 28 |
U.S. Gene Therapy Market,
By Gene Type, 2020-2030 (USD Million) |
|
Table 29 |
U.S. Gene Therapy Market,
By Delivery Method, 2020-2030 (USD Million) |
|
Table 30 |
Canada Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 31 |
Canada Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 32 |
Canada Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 33 |
Canada Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 34 |
Europe Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 35 |
Europe Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 36 |
Europe Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 37 |
EuropeGene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 38 |
Europe Gene Therapy
Market, By Country, 2020-2030 (USD Million) |
|
Table 39 |
Germany Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 40 |
Germany Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 41 |
Germany Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 42 |
Germany Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 43 |
U.K. Gene Therapy Market,
By Vectors Type, 2020-2030 (USD Million) |
|
Table 44 |
U.K. Gene Therapy Market,
By Indication Type, 2020-2030 (USD Million) |
|
Table 45 |
U.K. Gene Therapy Market,
By Gene Type, 2020-2030 (USD Million) |
|
Table 46 |
U.K. Gene Therapy Market,
By Delivery Method, 2020-2030 (USD Million) |
|
Table 47 |
France Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 48 |
France Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 49 |
France Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 50 |
France Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 51 |
Spain Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 52 |
Spain Gene Therapy Market,
By Indication Type, 2020-2030 (USD Million) |
|
Table 53 |
Spain Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 54 |
Spain Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 55 |
Italy Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 56 |
Italy Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 57 |
Italy Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 58 |
Italy Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 59 |
Rest of Europe Gene
Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 60 |
Rest of Europe Gene
Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 61 |
Rest of Europe Gene
Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 62 |
Rest of Europe Gene
Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 63 |
Asia Pacific Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 64 |
Asia Pacific Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 65 |
Asia Pacific Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 66 |
Asia Pacific Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 67 |
Asia Pacific Gene Therapy
Market, By Country, 2020-2030 (USD Million) |
|
Table 68 |
India Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 69 |
India Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 70 |
India Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 71 |
India Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 72 |
Japan Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 73 |
Japan Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 74 |
Japan Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 75 |
Japan Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 76 |
China Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 77 |
China Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 78 |
China Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 79 |
China Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 80 |
South Korea Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 81 |
South Korea Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 82 |
South Korea Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 83 |
South Korea Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 84 |
Australia Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 85 |
Australia Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 86 |
Australia Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 87 |
Australia Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 88 |
Rest of Asia Pacific Gene
Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 89 |
Rest of Asia Pacific Gene
Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 90 |
Rest of Asia Pacific Gene
Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 91 |
Rest of Asia Pacific Gene
Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 92 |
Middle East & Africa
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 93 |
Middle East &
AfricaGene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 94 |
Middle East & Africa
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 95 |
Middle East & Africa
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 96 |
Middle East & Africa
Gene Therapy Market, By Country, 2020-2030 (USD Million) |
|
Table 97 |
UAE Gene Therapy Market,
By Vectors Type, 2020-2030 (USD Million) |
|
Table 98 |
UAE Gene Therapy Market,
By Indication Type, 2020-2030 (USD Million) |
|
Table 99 |
UAE Gene Therapy Market,
By Gene Type, 2020-2030 (USD Million) |
|
Table 100 |
UAE Gene Therapy Market,
By Delivery Method, 2020-2030 (USD Million) |
|
Table 101 |
Saudi Arabia Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 102 |
Saudi Arabia Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 103 |
Saudi Arabia Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 104 |
Saudi Arabia Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 105 |
South Africa Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 106 |
South Africa Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 107 |
South Africa Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 108 |
South Africa Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 109 |
Rest of Middle East &
Africa Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 110 |
Rest of Middle East &
Africa Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 111 |
Rest of Middle East &
Africa Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 112 |
Rest of Middle East &
Africa Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 113 |
Latin America Gene
Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 114 |
Latin America Gene
Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 115 |
Latin America Gene
Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 116 |
Latin America Gene
Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 117 |
Latin America Gene
Therapy Market, By Country, 2020-2030 (USD Million) |
|
Table 118 |
Brazil Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 119 |
Brazil Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 120 |
Brazil Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 121 |
Brazil Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 122 |
Mexico Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 123 |
Mexico Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 124 |
Mexico Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 125 |
Mexico Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 126 |
Argentina Gene Therapy
Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 127 |
Argentina Gene Therapy
Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 128 |
Argentina Gene Therapy
Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 129 |
Argentina Gene Therapy
Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 130 |
Rest of Latin America
Gene Therapy Market, By Vectors Type, 2020-2030 (USD Million) |
|
Table 131 |
Rest of Latin America
Gene Therapy Market, By Indication Type, 2020-2030 (USD Million) |
|
Table 132 |
Rest of Latin America
Gene Therapy Market, By Gene Type, 2020-2030 (USD Million) |
|
Table 133 |
Rest of Latin America
Gene Therapy Market, By Delivery Method, 2020-2030 (USD Million) |
|
Table 134 |
Product Launch &
Development in The Gene Therapy Market, 2020-2022 |
|
Table 135 |
Investment and Expansion
in The Gene Therapy Market, 2020-2022 |
|
Table 136 |
Partnership &
Collaboration in The Gene Therapy Market, 2020-2022 |
|
Table 137 |
Merger & Acquisition
in The Gene Therapy Market, 2020-2022 |
|
List of Figures |
|
|
Figure 1 |
Research Methodology |
|
Figure 2 |
Summary Snapshot Market
Size and Forecast, USD Million, 2022 & 2030 |
|
Figure 3 |
Global Gene Therapy
Market Segmentation & Impact Analysis |
|
Figure 4 |
Regulatory Analysis |
|
Figure 5 |
COVID-19 Impact analysis
on Gene Therapy Market |
|
Figure 6 |
Market Revenue Share by
Manufacturers |
|
Figure 7 |
Gene Therapy Market, By
Vectors Type (Market Size and Forecast by Value - USD Million, 2022 &
2030) |
|
Figure 8 |
Gene Therapy Market, By
Indication Type (Market Size and Forecast by Value - USD Million, 2022 &
2030) |
|
Figure 9 |
Gene Therapy Market, By
Gene Type (Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
Figure 10 |
Gene Therapy Market, By
Delivery Method (Market Size and Forecast by Value - USD Million, 2022 &
2030) |
|
Figure 11 |
Gene Therapy Market, By
Region (Market Size and Forecast by Value - USD Million, 2022 & 2030) |
1.
Research Sources
We at Zettabyte Analytics have a
detailed and related research methodology focussed on estimating the market
size and forecasted value for the given market. Comprehensive research
objectives and scope were obtained through secondary research of the parent and
peer markets. The next step was to validate our research by various market
models and primary research. Both top-down and bottom-up approaches were
employed to estimate the market. In addition to all the research reports, data
triangulation is one of the procedures used to evaluate the market size of
segments and sub-segments.
Research Methodology
1.1. Secondary Research
The secondary research study involves various sources and databases used
to analyze and collect information for the market-oriented survey of a specific
market. We use multiple databases for our exhaustive secondary research, such
as Factiva, Dun & Bradstreet, Bloomberg, Research article, Annual reports,
Press Release, and SEC filings of significant companies. Apart from this, a
dedicated set of teams continuously extracts data of key industry players and
makes an extensive and unique segmentation related to the latest market
development.
1.2. Primary Research
The primary research includes gathering data from specific domain
experts through a detailed questionnaire, emails, telephonic interviews, and
web-based surveys. The primary interviewees for this study include an expert
from the demand and supply side, such as CEOs, VPs, directors, sales heads, and
marketing managers of tire 1,2, and 3 companies across the globe.
1.3. Data Triangulation
The data triangulation is very important for any market study, thus we
at Zettabyte Analytics focus on at least three sources to ensure a high level
of accuracy. The data is triangulated by studying various factors and trends
from both supply and demand side. All the reports published and stored in our
repository follows a detailed process to obtain a reliable insight for our
clients.
1.4. In-House Verification
To validate the segmentation
and verify the data collected, our market expert ensures whether our research
analyst is considering fine distinction before analyzing the market.
1.5. Reporting
In the end,
presenting our research reports complied in a different format for straightforward
valuation such as ppt, pdf, and excel data pack is done.
+1 716 953 3077
sales@zettabyteanalytics.com
109 S Warren St, Syracuse, NY 13202, United States